-+ 0.00%
-+ 0.00%
-+ 0.00%

Senti Biosciences Holdings to spin off gene-circuit pipeline including SENTI-202 into NewCo for CVR worth up to $60 million

PUBT·07/15/2026 11:32:36
Listen to the news
Senti Biosciences Holdings to spin off gene-circuit pipeline including SENTI-202 into NewCo for CVR worth up to $60 million
  • Senti Biosciences Holdings unveiled a reorganization to split off its Gene-Circuit pipeline, including AML therapy SENTI-202, into a new privately held biotech.
  • NewCo, controlled by affiliates of major investor Celadon, will acquire the assets in exchange for a contingent value right for equity holders.
  • CVR offers up to USD 60 million over seven years, tied to SENTI-202 BLA filing, FDA approval, and commercial sales milestones.
  • Remaining company plans to seek new financing, refocusing on Regulator Dial-powered controllable genetic medicines and early-stage programs.
  • Transaction requires stockholder approval and customary closing conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Holdings Inc. published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.